StockDriftsStockDriftsTop 5 Gilead Sciences INC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| RCUS | Arcus Biosciences Inc. | 58.76% | 31.42M | $968.8M | +0.00%(+0) | $14.93(+88.83%) | 2026-06-30 | |
| GLPG | Lakefront Biotherapeutics | 30.34% | 16.71M | $500.2M | +0.00%(+0) | $28.15(-4.39%) | 2026-06-30 | |
| ASMB | Assembly Biosciences Inc. | 8.3% | 4.98M | $136.8M | +10.47%(+471.70K) | $19.51(+35.30%) | 2026-06-30 | |
| KYTX | Kyverna Therapeutics Inc. | 2.23% | 4.13M | $36.8M | +0.00%(+0) | $4.31(+84.24%) | 2026-06-30 | |
| XLO | Xilio Therapeutics Inc. | 0.38% | 650.4K | $6.2M | +0.00%(+0) | $12.20(-24.78%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (6 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +57.67% |
| Top 20 Holdings Unweighted | — | — | — | — | +64.56% |
Gilead Sciences INC reports $1.65B in US-listed equity holdings across 5 positions in its most recent 13F filing. Its largest disclosed positions are RCUS (58.8%), GLPG (30.3%) and ASMB (8.3%). The top 20 holdings account for 100.01% of reported assets. Its disclosed equity book has returned +57.67% cumulatively over 6 quarters. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Gilead Sciences INC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Gilead Sciences INC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 882095). View Gilead Sciences INC’s 13F filings on SEC